Curated News
By: NewsRamp Editorial Staff
August 18, 2026
Cardio Diagnostics Launches CLIA-Certified Lab for Precision Heart Tests
TLDR
- Cardio Diagnostics' new in-house lab cuts costs and boosts margins, giving it a competitive edge in precision cardiovascular testing.
- Cardio Diagnostics launched a CLIA-certified lab in Iowa, ensuring end-to-end processing for its Epi+Gen CHD and PrecisionCHD tests.
- This lab enhances accessibility and precision in cardiovascular care, potentially improving patient outcomes through faster, more reliable testing.
- Cardio Diagnostics' lab, with zero deficiencies on inspection, marks a milestone in bringing advanced epigenetic testing in-house.
Impact - Why it Matters
This news matters because it demonstrates Cardio Diagnostics' commitment to scaling its operations and improving the reliability and efficiency of its cardiovascular tests. By bringing lab processing in-house, the company can reduce costs, shorten turnaround times, and maintain strict quality control, which could lead to better patient outcomes and broader adoption of its precision medicine approach. For investors, this move signals potential for improved margins and competitive advantage in the growing precision cardiology market.
Summary
Cardio Diagnostics Holdings (NASDAQ: CDIO), an AI-driven precision cardiovascular medicine company, has officially launched its in-house, high-complexity CLIA-certified laboratory in Iowa City, Iowa. This strategic move gives the company end-to-end control over processing its multi-omics clinical tests, Epi+Gen CHD(TM) and PrecisionCHD(TM), from sample receipt to result delivery. The facility received its federal Clinical Laboratory Improvement Amendments (CLIA) license after an inspection with no deficiencies and has secured out-of-state licenses from California, Maryland, Rhode Island, and Pennsylvania, with New York licensing in progress. By bringing processing in-house, Cardio Diagnostics expects to gain greater control over costs, quality, and turnaround times, while improving unit economics as sample volume grows. The company targets gross margins of approximately 40% at scale, with current turnaround times of seven to ten business days from sample receipt. The facility also includes a research laboratory supporting the company's work in precision epigenetic methods and development of a high-precision cardiovascular health monitoring system.
Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The company was formed to further develop and commercialize clinical tests by leveraging a proprietary AI-driven Integrated Genetic-Epigenetic Engine for cardiovascular disease. This launch marks a significant milestone in the company's operational capabilities, positioning it to become a leading medical technology company for improving prevention, detection, and treatment of cardiovascular disease. The full press release is available at https://ibn.fm/44Xz1. For the latest news and updates on CDIO, visit the company's newsroom at https://ibn.fm/CDIO.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Cardio Diagnostics Launches CLIA-Certified Lab for Precision Heart Tests
